25.5 million to accelerate the development of Advanced Therapy Medicines

CNC and iBET participate in the European project ARDAT, which aims to standardize and accelerate the development of Advanced Therapy Medicines (ATMPs). This project is supported by Europe’s Innovative Medicines Initiative (IMI) with €25.5 million.

ATMPs have unprecedented potential to significantly improve patients’ life quality. ATMP research is growing exponentially, it is expected that up to 10 to 20 new drug applications submitted per year to the FDA by 2025 are ATMPs. As an emerging field, ATMP knowledge is still fragmented and siloed within organizations with little opportunity to share best practices and information, ARDAT project aims to break these silos and streamline ATMP development.

The ARDAT project - Accelerating Research and Innovation for Advanced Therapies - is a 5-year pre-competitive consortium, supported by the Innovative Medicines Initiative (IMI), a program co-financed by the European Union and the European Federation of Pharmaceutical Industry and Associations (EPFIA) and led by Pfizer and the University of Sheffield.

ARDAT is a 5-year precompetitive consortium, led by Pfizer and University of Sheffield, UK.

Hugo Soares, Sara Varela Amaral and Luís Pereira de Almeida